All In Biotech

NDA 018371 · Otsuka Icu Medcl

Potassium Chloride 30meq In Dextrose 5% In Plastic Container

Dextrose, Potassium Chloride · Injection

Last checked: Nov 20, 2026Latest source record: Sep 8, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1980

May 29, 1980

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3,797

712 Phase 3, 359 recruiting

FAERS reports

15

8 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 30, 2025.

INDICATIONS AND USAGE This solution is indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 29, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER · DEXTROSE 5GM/100ML; POTASSIUM CHLORIDE 224MG/100ML · INJECTABLE, INJECTION · Discontinued
  • POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER · DEXTROSE 5GM/100ML; POTASSIUM CHLORIDE 149MG/100ML · INJECTABLE, INJECTION · Prescription
  • POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER · DEXTROSE 5GM/100ML; POTASSIUM CHLORIDE 298MG/100ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextrose" as an intervention, any sponsor and status, largest first.

All 3,797 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia3
  • renal ischaemia3
  • anaemia2
  • burkholderia test positive2
  • covid-192
  • endotracheal intubation2
  • intercepted product selection error2
  • product label confusion2
  • product name confusion2
  • pyrexia2
  • respiratory rate decreased2
  • white blood cell count decreased2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
20163
20182
20211
20222
20244
20251
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,414 on PubMed

Sponsor: Otsuka · Also marketed as Potassium Chloride 20meq In Dextrose 5% In Plastic Container, Potassium Chloride 40meq In Dextrose 5% In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.